Review concluded regarding general reimbursement for Adepend®

The Danish Medicines Agency has completed its review of an application for general reimbursement for Adepend®.

The product is neither eligible for general nor general conditional reimbursement.

Adepend® is used as part of treatment of alcoholism.

When we compare treatment with Adepend® with treatment with Antabuse, we assess that the price of the medicine is not reasonable relative to its therapeutic value.

The reimbursement status of Adepend® will be reassessed in connection with the regular reassessment of the reimbursement status of all medicines.

Please find the Reimbursement Committee recommendation and the Danish Medicines Agency’s decision in the box to the right (in Danish only).